Deprecated: Required parameter $cat_id follows optional parameter $type in /data/ebiomall/systems/hong.php on line 2088

Deprecated: Required parameter $where follows optional parameter $tree_id in /data/ebiomall/systems/hlb.php on line 3505
Cellagentech/SD-169 | p38 MAPK inhibitor/C7216-10/10 mg (powder)-蚂蚁淘商城
新闻动态

Cellagentech/SD-169 | p38 MAPK inhibitor/C7216-10/10 mg (powder)

  
  2026-08-24
  
Product Description

SD169 is an indole-5-carboxamide, orally-available, ATP-competitive, a-selective p38 MAPK inhibitor that targets a wide variety of inflammatory cells, including neutrophils, monocytes, macrophages, B and CD4+ T cells, and endothelial cells. [1] Through interactions with Schwann cell and TNF activity, SD169 promotes axonal regeneration in peripheral nerves. [2]SD169 has been shown to reduce myeloma-induced osteolytic bone lesions and restored bone mass by downregulating osteoclastogenesis and osteoblastogenesis in xenografted primary myeloma-SCID-hu or myeloma cell line-SCID mouse models. [3] SD169 was also shown downregulates pp38 in myeloma cells in vitro and in vivo.In the diabetes therapeutic area, SD169 significantly reduces p38 and HSP60 expression in T cells of the pancreatic beta islets. In studies using hyperglycemic NOD mice, SD169 treatment lowered blood glucose and improved glucose homeostasis. [4]


Technical information:

Chemical Formula: C9H8N2O
CAS #: 1670-87-7
Molecular Weight: 160.17
Purity: >98%
Appearance: White
Chemical Name: 1H-indole-5-carboxamide
Solubility: Up to 22 mM in DMSO
Synonyms: SD-169, SD169

Shipping Condition: The product is shipped in a glass vial at ambient temperature. Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. Medicherla et al., p38 MAPK inhibition reduces diabetes-induced impairment of wound healing. Diabetes, Metab. Syndr. Obes. 2009, 2, 91-100. Pubmed ID: 21437122
2. Myers et al., Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp. Neurol. 2003, 184, 606-614. Pubmed ID: 14769353
3. Yang et al., Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia, 2012, 26, 2114-2123. Pubmed ID: 22425892
4. Medicherla et al., J. Pharmacol. Exp. Ther. 2006, 318(1), 99-107. Pubmed ID: 14769353

本文链接: https://www.ebiomall.cn/b352-xona/info-1566021507.html

免责声明 本文仅代表作者个人观点,与本网无关。其创作性以及文中陈述文字和内容未经本站证实,对本文以及其中全部或者部分内容、文字的真实性、完整性、及时性本站不做任何保证或承诺,请读者仅作参考,并请自行核实相关内容。
版权声明 未经蚂蚁淘授权不得转载、摘编或利用其他方式使用上述作品。已经经本网授权使用作品的,应该授权范围内使用,并注明“来源:蚂蚁淘”。违反上述声明者,本网将追究其相关法律责任。
没有了